Age-standardized death rates from bladder cancer fell globally between 1990 and 2019


Clear global decreases in the age-standardized death rate and disability-adjusted life-years rate have been observed among people with bladder cancer from 1990 to 2019, despite some countries experiencing a decline. increase in these rates, according to the results of the Global Burden of Diseases, Injuries and Risk Factors Study 2019 published in BMJ Global Health.

Specifically, over the period 1990 to 2019, the age-standardized death rate decreased by 15.7% (95% uncertainty interval [UI], 8.6% to 21.0%), and the age-standardized disability-adjusted life years (DALY) rate experienced a significant decrease of 18.6% (95% insurance- unemployment, 11.2% to 24.3%). These bladder cancer cases accounted for 4.39 million (95% IU, 4.09-4.70) DALYs in 2019.

“This study found considerable variation between countries in the burden of bladder cancer over the study period,” the investigators wrote. “Although age-standardized death rates and DALY rates declined from 1990 to 2019, some countries saw increases in these rates.”

In 2019, investigators reported that there were 524,000 cases of bladder cancer (95% IU, 476,000-569,000) and 229,000 deaths from bladder cancer (95% IU, 211,000-243,000 ) in the world. Among these cases, the age-standardized rate was 6.5 (95% IU, 5.9-7.1) per 100,000, which increased by 4% (95% IU, -4.3 % -13.5%) between 1990 and 2019. Additionally, investigators reported an age-standardized death rate of 2.9 (95% IU, 2.7-3.1) per 100,000.

In 2019, the age-standardized incidence rates of bladder cancer per 100,000 were highest in Western Europe (14.9; 95% IU, 12.8-17.3), Central Europe ( 12.6; 95% IU, 11.0-14.3), and in North Africa and the Middle East. Is (9.6; 95% IU, 8.1-11.4). The lowest age-standardized incidence rates were observed in South Asia (2.4; 95% IU, 2.1-2.7), Oceania (2.5; 95% IU , 2.0 to 3.1) and in Andean Latin America (2.5; 95% IU, 2.1-3.1).

In terms of age-standardized death rates per 100,000, the highest rates were observed in Central Europe (5.3; 95% IU, 4.7-6.0), Western Europe (4 , 8; 95% IU, 4.3 to 5.1) and in North Africa and the Middle East (4.1; 95% IU, 3.5-4.8). The lowest rates were found in Central Latin America (1.5; 95% IU, 1.3-1.8), Andean Latin America (1.6; 95% IU, 1.3-2.0 ) and Southeast Asia (1.8; 95% IU, 1.5-2.0).

In comparison, regions where age-standardized global incidence rates have increased in some regions of the global burden of disease, notably East Asia (55.6%; 95% IU, 26.1 % -95.8%), North Africa and the Middle East (52.5%; 21.3% -107.1%) and Central Europe (50.3%; 95% IU, 30.3 % -70.7%). Central Asia (17.9%; UI 95%, 1.8% to 42.7%) experienced a significant increase in age-standardized death rates.

When analyzed by gender, global bladder cancer incidence rates per 100,000 in 2019 were higher among men than women in all age subgroups.

In terms of risk factors, smoking has been attributed to 36.8% (95% IU, 28.5% to 44.0%) of bladder cancer DALYs, with a high frequency in men (43, 7%; 95% IU, 34.0% to 51.8%) compared to females (15.2%; 95% IU, 10.9% -19.4%). Additionally, approximately 9.1% (95% IU, 1.9% -19.6%) of DALYs may be related to high fasting blood sugar, including 9.3% (95% IU, 1.6% – 20.9%) in men and 8.4% (95% IU, 1.6% to 19.1%) in women.

“National policy makers should consider allocating resources to address bladder cancer risk factors, as part of comprehensive prevention programs based on their national estimates, rather than global or regional estimates, which may be misleading, ”the investigators concluded.

Reference

Safiri S, Kolahi AA, Naghavi M; Contributors on the global burden of disease for bladder cancer. Global, regional and national burden of bladder cancer and its attributable risk factors in 204 countries and territories, 1990-2019: a systematic review for the Global Burden of Disease 2019 study. BMJ Global Health. 2021; 6 (11): e004128. doi: 10.1136 / bmjgh-2020-004128


Comments are closed.